The Universal Vaccine Implant (UVI) is a novel, proprietary, precision engineered unit solid dose vaccine formulation. Each UVI consists of the vaccine(s) and approved excipients that are utilised in traditional lyophilised vaccine or biological formulations. All benefit from enhanced thermal stability, which both aids administration, extends shelf-life and optimises stockpiling.
Each UVI is 0.85mm in diameter and 4mm in length with a solid volume of injection of approximately 2.5 microlitres, or about 250 times less than a typical intramuscular liquid delivery. It has a sharp tip and mechanical strength designed to ensure 100% skin penetration each and every time.
The physicochemical properties of the UVI can be fine-tuned so that the dissolution of the vaccine into the dermis layer of the skin is rapid (minutes) or slow (weeks), or even pulsatile. This can optimize the interaction and recruitment of immune cells and antibodies to generate a long-lived immune response with potential for regimen sparing.
Enesi Pharma can employ one of three manufacturing processes, namely extrusion, micro-tableting, and polymer moulding, to match the required robustness of the vaccine in development. All three processes have the capability for high-throughput scaleup, and ImplaVax® can offer local, global and portable approach to commercial-scale vaccine manufacture.